There is nothing in legislation that prevents the use of PGDs in clinical trials, studies or pilots if the medicine has a product licence and all other legal and good practice requirements relating to PGDs are met.
Often medicines administered or supplied under a PGD as part of a clinical trial, study or pilot are not actually part of the investigation which is more commonly focused on the service design, delivery or patient group. Examples include use of a vaccine in a population outside the national immunisation schedule or the supply of PreP as a programme pilot.
The UK licensing status of the medications involved must be considered. If the medication use is off label this is permitted under a PGD, but this must be acknowledged within the PGD as stated within the NICE guidance and must be clearly justified by best clinical practice. Unlicensed medications (those without a UK licence or Market Authorisation) cannot be supplied or administered under a PGD in any circumstance.
Organisations may wish to seek advice and support from their local Clinical Trials team.